Epigenetic regulation of human cytomegalovirus latency: An update

Epigenomics

Volumn 6, Issue 5, 2014, Pages 533-546

  Kumar, Amit ^a   Herbein, Georges ^a  

^a UNIVERSITÉ DE FRANCHE COMTÉ   (France)

Author keywords

[No Author keywords available]

Indexed keywords

EMBRYONIC ECTODERM DEVELOPMENT PROTEIN; INTERLEUKIN 10; MICRORNA; POLYCOMB REPRESSIVE COMPLEX 2; TRANSCRIPTION FACTOR GATA 2; ZINC FINGER PROTEIN;

CELL DIFFERENTIATION; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; CHROMATIN IMMUNOPRECIPITATION; CHROMATIN STRUCTURE; CONGENITAL INFECTION; CYTOMEGALOVIRUS INFECTION; DENDRITIC CELL; GENETIC REGULATION; GRAFT RECIPIENT; HISTONE METHYLATION; HUMAN CYTOMEGALOVIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; MIXED INFECTION; NEOPLASM; NONHUMAN; PATHOPHYSIOLOGY; REVIEW; RIBOSOME; VIRUS LATENCY; VIRUS REACTIVATION; CYTOMEGALOVIRUS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; HUMAN; PHYSIOLOGY; VIROLOGY;

HUMAN HERPESVIRUS 5;

CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION; GENE EXPRESSION REGULATION, VIRAL; HUMANS; VIRUS LATENCY;

EID: 84913607311     PISSN: 17501911     EISSN: 1750192X     Source Type: Journal    
DOI: 10.2217/epi.14.41     Document Type: Review

References (156)

1. Bate SL, Dollard SC, Cannon MJ. Cytomegalovirus seroprevalence in the United States. The national health and nutrition examination surveys, 1988-2004. Clin. Infect. Dis. 50(11), 1439-1447 (2010).
2. Crough T, Khanna R. Immunobiology of human cytomegalovirus: from bench to bedside. Clin. Microbiol. Rev. 22(1), 76-98, (2009).
3. Manicklal S, Emery VC, Lazzarotto T, Boppana SB, Gupta RK. The 'silent' global burden of congenital cytomegalovirus. Clin. Microbiol. Rev. 26(1), 86-102 (2013).
4. Davison AJ, Dolan A, Akter P et al. The human cytomegalovirus genome revisited. Comparison with the chimpanzee cytomegalovirus genome. J. Gen. Virol. 84(Pt 1), 17-28 (2003).
5. Murphy E, Rigoutsos I, Shibuya T, Shenk TE. Reevaluation of human cytomegalovirus coding potential. Proc. Natl Acad. Sci. USA 100(23), 13585-13590 (2003).
6. Murphy E, Yu D, Grimwood J et al. Coding potential of laboratory and clinical strains of human cytomegalovirus. Proc. Natl Acad. Sci. USA 100(25), 14976-14981 (2003).
7. Stern-Ginossar N, Weisburd B, Michalski A et al. Decoding human cytomegalovirus. Science 338(6110), 1088-1093 (2012).
8. Zhang Z, Evers DL, McCarville J F, Dantonel JC, Huong SM, Huang ES. Evidence that the human cytomegalovirus IE2-86 protein binds Mdm2 and facilitates mdm2 degradation. J. Virol. 80(8), 3833-3843 (2006).
9. Yee LF, Lin PL, Stinski MF. Ectopic expression of HCMV IE72 and IE86 proteins is suffcient to induce early gene expression but not production of infectious virus in undifferentiated promonocytic THP-1 cells. Virology 363(1), 174-188 (2007).
10. Hwang ES, Zhang Z, Cai H et al. Human cytomegalovirus IE1-72 protein interacts with p53 and inhibits p53-dependent transactivation by a mechanism different from that of IE2-86 protein. J. Virol. 83(23), 12388-12398 (2009).
11. Webel R, Hakki M, Prichard M, Rawlinson WD, Marschall M, Chou S. Differential properties of cytomegalovirus pUL97 kinase isoforms affect viral replication and maribavir susceptibility J. Virol. 88(9), 4776-4785 (2014).
12. Kalejta RF. Tegument proteins of human cytomegalovirus. Microbiol. Mol. Biol. Rev. 72(2), 249-265 (2008).
13. Meier J, Lienicke U, Tschirch E, Krüger DH, Wauer RR, Prösch S. Human cytomegalovirus reactivation during lactation and mother-to-child transmission in preterm infants. J. Clin. Microbiol. 43(3), 1318-1324 (2005).
14. Mehler K, Oberthuer A, Lang-Roth R, Kribs A. High rate of symptomatic cytomegalovirus infection in extremely low gestational age preterm infants of 22-24 weeks' gestation after transmission via breast milk. Neonatology 105(1), 27-32 (2014).
15. Schleiss MR. Developing a vaccine against congenital cytomegalovirus (CMV) infection. What have we learned from animal models? Where should we go next? Future Virol. 8(12), 1161-1182 (2013).
16. Liu XF, Wang X, Yan S, Zhang Z, Abecassis M, Hummel M. Epigenetic control of cytomegalovirus latency and reactivation. Viruses 5(5), 1325-1345 (2013).
17. Sinclair J, Sissons P. Latency and reactivation of human cytomegalovirus. J. Gen. Virol. 87(Pt 7), 1763-1779 (2006).
18. Kumar A, Abbas W, Herbein G. HIV-1 latency in monocytes/macrophages. Viruses 6(4), 1837-1860 (2014).
19. Slobedman B, Mocarski ES. Quantitative analysis of latent human cytomegalovirus. J. Virol. 73(6), 4806-4812 (1999).
20. Bolovan-Fritts CA, Mocarski ES, Wiedeman JA. Peripheral blood CD14(+) cells from healthy subjects carry a circular conformation of latent cytomegalovirus genome. Blood 93 (1), 394-398 (1999).
21. Mendelson M, Monard S, Sissons P, Sinclair J. Detection of endogenous human cytomegalovirus in CD34+ bone marrow progenitors. J. Gen. Virol. 77 (Pt 12), 3099-3102 (1996).
22. Reeves MB, MacAry PA, Lehner PJ, Sissons JG, Sinclair JH. Latency, chromatin remodeling, and reactivation of human cytomegalovirus in the dendritic cells of healthy carriers. Proc. Natl Acad. Sci. USA 102(11), 4140-4145 (2005).
23. Taylor-Wiedeman J, Sissons JG, Borysiewicz LK, Sinclair JH. Monocytes are a major site of persistence of human cytomegalovirus in peripheral blood mononuclear cells. J. Gen. Virol. 72 (Pt 9), 2059-2064 (1991).
24. Tey SK, Goodrum F, Khanna R. CD8+ T-cell recognition of human cytomegalovirus latency-associated determinant pUL138. J. Gen. Virol. 91(Pt 8), 2040-2048 (2010).
25. Egger G, Liang G, Aparicio A, Jones PA. Epigenetics in human disease and prospects for epigenetic therapy. Nature 429(6990), 457-463 (2004).
26. Cavalli G. Chromatin and epigenetics in development: blending cellular memory with cell fate plasticity Development 133(11), 2089-2094 (2006).
27. Feinberg AP, Ohlsson R, Henikoff, S. The epigenetic progenitor origin of human cancer. Nat. Rev. Genet. 7(1), 21-33 (2006).
28. Fu M, Gao Y, Zhou Q et al. Human cytomegalovirus latent infection alters the expression of cellular and viral microRNA. Gene 536(2), 272-278 (2014).
29. Liu X, Chen X, Yu X et al. Regulation of microRNAs by epigenetics and their interplay involved in cancer. J. Exp. Clin. Cancer Res. 32(1), 96 (2013).
30. O'Connor CM, DiMaggio PA Jr, Shenk T, Garcia BA. Quantitative Proteomic Discovery of Dynamic Epigenome Changes that Control Human Cytomegalovirus (HCMV) Infection. Mol. Cell. Proteomics. 13 (9), 2399-2410 (2014)
31. Pavelin J, Reynolds N, Chiweshe S, Wu G, Tiribassi R, Grey F. Systematic microRNA analysis identifes ATP6V0C as an essential host factor for human cytomegalovirus replication. PLoS Pathog 9(12), e1003820 (2013).
32. Rode K, Dohner K, Binz A et al. Uncoupling uncoating of herpes simplex virus genomes from their nuclear import and gene expression. J. Virol. 85(9), 4271-4283 (2011).
33. Nevels M, Nitzsche A, Paulus C. How to control an infectious bead string: nucleosome-based regulation and targeting of herpesvirus chromatin. Rev. Med. Virol. 21(3), 154-180 (2011).
34. Nitzsche A, Paulus C, Nevels M. Temporal dynamics of cytomegalovirus chromatin assembly in productively infected human cells. J. Virol. 82(22), 11167-11180 (2008).
35. Nitzsche A, Steinhäusser C, Mücke K, Paulus C, Nevels M. Histone H3 lysine 4 methylation marks postreplicative human cytomegalovirus chromatin. J. Virol. 86(18), 9817-9827 (2012).
36. Sinclair J. Chromatin structure regulates human cytomegalovirus gene expression during latency, reactivation and lytic infection. Biochim. Biophys. Acta 1799(3-4), 286-295 (2010).
37. Bego M, Maciejewski J, Khaiboullina S, Pari G, St JS. Characterization of an antisense transcript spanning the UL81-82 locus of human cytomegalovirus. J. Virol. 79(17), 11022-11034 (2005).
38. Bego MG, Keyes LR, Maciejewski J, St Jeor SC. Human cytomegalovirus latency-associated protein LUNA is expressed during HCMV infections in vivo. Arch. Virol. 156(10), 1847-1851 (2011).
39. Rossetto CC, Tarrant-Elorza M, Pari GS. Cis and trans acting factors involved in human cytomegalovirus experimental and natural latent infection of CD14 (+) monocytes and CD34 (+) cells. PLoS Pathog. 9(5), e1003366 (2013).
40. Reeves M, Sinclair J. Regulation of human cytomegalovirus transcription in latency: beyond the major immediate-early promoter. Viruses 5(6), 1395-1413 (2013).
41. Reeves MB, Lehner PJ, Sissons JG, Sinclair JH. An in vitro model for the regulation of human cytomegalovirus latency and reactivation in dendritic cells by chromatin remodeling. J. Gen. Virol. 86(Pt 11), 2949-2954 (2005).
42. Stinski MF, Isomura H. Role of the cytomegalovirus major immediate early enhancer in acute infection and reactivation from latency. Med. Microbiol. Immunol. 197(2), 223-231 (2008).
43. Groves IJ, Reeves MB, Sinclair JH. Lytic infection of permissive cells with human cytomegalovirus is regulated by an intrinsic 'pre-immediate-early' repression of viral gene expression mediated by histone post-translational modifcation. J. Gen. Virol. 90(Pt 10), 2364-2374 (2009).
44. Ioudinkova E, Arcangeletti MC, Rynditch A et al. Control of human cytomegalovirus gene expression by differential histone modifcations during lytic and latent infection of a monocytic cell line. Gene 384, 120-128 (2006).
45. Nevels M, Paulus C, Shenk T. Human cytomegalovirus immediate-early 1 protein facilitates viral replication by antagonizing histone deacetylation. Proc. Natl. Acad. Sci. USA 101(49), 17234-17239 (2004).
46. Reeves M, Sinclair J. Aspects of human cytomegalovirus latency and reactivation. Curr. Top. Microbiol. Immunol. 325, 297-313 (2008).
47. Reeves MB. Chromatin-mediated regulation of cytomegalovirus gene expression. Virus Res. 157(2), 134-143 (2011).
48. Liu R, Baillie J, Sissons JG, Sinclair JH. The transcription factor YY1 binds to negative regulatory elements in the human cytomegalovirus major immediate early enhancer/promoter and mediates repression in non-permissive cells. Nucleic Acids Res. 22 (13), 2453-2459 (1994).
49. Bain M, Mendelson M, Sinclair J. Ets-2 repressor factor (ERF) mediates repression of the human cytomegalovirus major immediate-early promoter in undifferentiated non-permissive cells. J. Gen. Virol. 84(Pt 1), 41-49 (2003).
50. Wright E, Bain M, Teague L, Murphy J, Sinclair J. Ets-2 repressor factor recruits histone deacetylase to silence human cytomegalovirus immediate-early gene expression in non-permissive cells. J. Gen. Virol. 86(Pt 3), 535-544 (2005).
51. Sourvinos G, Morou A, Sanidas I et al. The downregulation of GFI1 by the EZH2-NDY1/KDM2B-JARID2 axis and by human cytomegalovirus (HCMV) associated factors allows the activation of the HCMV major IE promoter and the transition to productive infection. PLoS Pathog. 10 (5), e1004136 (2014).
52. David BC, Nicole GV, Dacia KL. Epigenetic regulation of latent HSV-1 gene expression. Biochim. Biophys. Acta. 1799(3-4), 246-256 (2010).
53. Chen HS, Lu F, Lieberman PM. Epigenetic regulation of EBV and KSHV latency. Curr. Opin. Virol. 3(3), 251-259 (2013).
54. Hirabayashi Y, Gotoh Y. Epigenetic control of neural precursor cell fate during development. Nat. Rev. Neurosci. 11(6), 377-388 (2010).
55. He A, Shen X, Ma Q et al. PRC2 directly methylates GATA4 and represses its transcriptional activity. Genes Dev. 26(1), 37-42 (2012).
56. Shen X, Liu Y, Hsu YJ et al. EZH1 mediates methylation on histone H3 lysine 27 and complements EZH2 in maintaining stem cell identity and executing pluripotency. Mol. Cell 32(4), 491-502 (2008).
57. Abraham CG, Kulesza CA. Polycomb repressive complex 2 targets murine cytomegalovirus chromatin for modifcation and associates with viral replication centers. PLoS One 7(1), e29410 (2012).
58. Kirmizis A, Bartley SM, Kuzmichev A et al. Silencing of human polycomb target genes is associated with methylation of histone H3 Lys 27. Genes Dev. 18(13), 1592-1605 (2004).
59. Kuzmichev A, Nishioka K, Erdjument-Bromage H, Tempst P, Reinberg D. Histone methyltransferase activity associated with a human multiprotein complex containing the Enhancer of Zeste protein. Genes Dev. 16(22), 2893-2905 (2002).
60. Zhao Y, Srivastava D. A developmental view of microRNA function. Trends Biochem. Sci. 32(4), 189-197 (2007).
61. Gottwein E. Roles of microRNAs in the life cycles of mammalian viruses. Curr. Top. Microbiol. Immunol. 371, 201-227 (2013).
62. tenOever BR. RNA viruses and the host microRNA machinery. Nat. Rev. Microbiol. 11(3), 169-180 (2013).
63. Tuddenham L, Pfeffer S. Roles and regulation of microRNAs in cytomegalovirus infection. Biochim. Biophys. Acta 1809(11-12), 613-622 (2011).
64. Barth S, Pfuhl T, Mamiani A et al. Epstein-Barr virus-encoded microRNA miR-BART2 down-regulates the viral DNA polymerase BALF5. Nucleic Acids Res. 36(2), 666-675 (2008).
65. Cai X, Lu S, Zhang Z, Gonzalez CM, Damania B, Cullen BR. Kaposi's sarcoma-associated herpesvirus expresses an array of viral microRNAs in latently infected cells. Proc. Natl Acad. Sci. USA 102 (15), 5570-5575 (2005).
66. Lei X, Bai Z, Ye F et al. Regulation of NF-kappaB inhibitor IkappaBalpha and viral replication by a KSHV microRNA. Nat. Cell Biol. 12(2), 193-199 (2010).
67. Grey F, Antoniewicz A, Allen E et al. Identifcation and characterization of human cytomegalovirus-encoded microRNAs. J. Virol. 79(18), 12095-12099 (2005).
68. Grey F, Meyers H, White EA, Spector DH, Nelson J. A human cytomegalovirus-encoded microRNA regulates expression of multiple viral genes involved in replication. PLoS Pathog. 3(11), e163 (2007).
69. Murphy E, Vanicek J, Robins H, Shenk T, Levine AJ. Suppression of immediate-early viral gene expression by herpesvirus-coded microRNAs: implications for latency. Proc. Natl Acad. Sci. USA 105(14), 5453-5458 (2008).
70. Stern-Ginossar N, Saleh N, Goldberg MD, Prichard M, Wolf DG, Mandelboim O. Analysis of human cytomegalovirus-encoded microRNA activity during infection. J. Virol. 83(20), 10684-10693 (2009).
71. Shen ZZ, Pan X, Miao LF et al. Comprehensive analysis of human cytomegalovirus microRNA expression during lytic and quiescent infection. PLoS One 9(2), e88531 (2014).
72. Poole E, McGregor Dallas SR, Colston J, Joseph RS, Sinclair J. Virally induced changes in cellular microRNAs maintain latency of human cytomegalovirus in CD34(+) progenitors. J. Gen. Virol. 92(Pt 7), 1539-1549 (2011).
73. Mocellin S, Marincola FM, Young HA. Interleukin-10 and the immune response against cancer: a counterpoint. J. Leukoc. Biol. 78(5), 1043-1051 (2005).
74. We eke s MP, Tan SY, Poole E et al. Latency-associated degradation of the MRP1 drug transporter during latent human cytomegalovirus infection. Science 340( 6129), 199-202 ( 2013).
75. Umashankar M, Petrucelli A, Cicchini L et al. A novel human cytomegalovirus locus modulates cell type-specifc outcomes of infection. PLoS Pathog. 7(12), e1002444 (2011).
76. Avdic S, Cao JZ, Cheung AK, Abendroth A, Slobedman B. Viral interleukin-10 expressed by human cytomegalovirus during the latent phase of infection modulates latently infected myeloid cell differentiation. J. Virol. 85(14), 7465-7471 (2011).
77. Arav-Boger R, Battaglia CA, Lazzarotto T et al. Cytomegalovirus (CMV)-encoded UL144 (truncated tumor necrosis factor receptor) and outcome of congenital CMV infection. J. Infect. Dis. 194(4), 464-473 (2006).
78. Suzuki H, Takatsuka S, Akashi H et al. Genome-wide profling of chromatin signatures reveals epigenetic regulation of MicroRNA genes in colorectal cancer. Cancer Res. 71(17), 5646-5658 (2011).
79. Iorio MV, Piovan C, Croce CM. Interplay between microRNAs and the epigenetic machinery. An intricate network. Biochim. Biophys. Acta 1799(10-12), 694-701 (2010).
80. Soderberg-Naucler C, Fish KN, Nelson JA. Reactivation of latent human cytomegalovirus by allogeneic stimulation of blood cells from healthy donors. Cell 91(1), 119-126 (1997).
81. Soderberg-Naucler C, Streblow DN, Fish KN, Allan-Yorke J, Smith PP, Nelson JA. Reactivation of latent human cytomegalovirus in CD14(+) monocytes is differentiation dependent. J. Virol. 75(16), 7543-7554 (2001).
82. Kondo K, Kaneshima H, Mocarski ES. Human cytomegalovirus latent infection of granulocyte-macrophage progenitors. Proc. Natl Acad. Sci. USA 91(25), 11879-11883 (1994).
83. Cheung AK, Abendroth A, Cunningham AL, Slobedman B. Viral gene expression during the establishment of human cytomegalovirus latent infection in myeloid progenitor cells. Blood 108(12), 3691-3699 (2006).
84. Fish KN, Stenglein SG, Ibanez C, Nelson JA. Cytomegalovirus persistence in macrophages and endothelial cells. Scand. J. Infect. Dis. Suppl. 99, 34-40 (1995).
85. Goodrum F, Reeves M, Sinclair J, High K, Shenk T. Human cytomegalovirus sequences expressed in latently infected individuals promote a latent infection in vitro. Blood 110(3), 937-945 (2007).
86. Hahn G, Jores R, Mocarski ES. Cytomegalovirus remains latent in a common precursor of dendritic and myeloid cells. Proc. Natl Acad. Sci. USA 95(7), 3937-3942 (1998).
87. Stevenson EV, Collins-McMillen D, Kim JH, Cieply SJ, Bentz GL, Yurochko AD. HCMV reprogramming of infected monocyte survival and differentiation: a Goldilocks phenomenon. Viruses 6(2), 782-807 (2014).
88. Goodrum FD, Jordan CT, High K, Shenk T Human cytomegalovirus gene expression during infection of primary hematopoietic progenitor cells. a model for latency. Proc. Natl Acad. Sci. USA 99(25), 16255-16260 (2002).
89. Slobedman B, Cao JZ, Avdic S et al. Human cytomegalovirus latent infection and associated viral gene expression. Future Microbiol. 5(6), 883-900 (2010).
90. Umashankar M, Goodrum F. Hematopoietic long-term culture (hLTC) for human cytomegalovirus latency and reactivation. Methods Mol. Biol. 1119, 99-112 (2014).
91. Goodrum F, Jordan CT, Terhune SS, High K, Shenk T Differential outcomes of human cytomegalovirus infection in primitive hematopoietic cell subpopulations. Blood 104(3), 687-695. (2004).
92. Petrucelli A, Rak M, Grainger L, Goodrum F. Characterization of a novel Golgi apparatus-localized latency determinant encoded by human cytomegalovirus. J. Virol. 83(11), 5615-5629 (2009).
93. Umashankar M, Rak M, Bughio F, Zagallo P, Caviness K, Goodrum FD. Antagonistic determinants controlling replicative and latent states of human cytomegalovirus infection. J. Virol. 88(11), 5987-6002 (2014).
94. Petrucelli A, Umashankar M, Zagallo P, Rak M, Goodrum F. Interactions between proteins encoded within the human cytomegalovirus UL133-UL138 locus. J. Virol. 86(16), 8653-8662 (2012).
95. Gatherer D, Seirafan S, Cunningham C et al. High-resolution human cytomegalovirus transcriptome. Proc. Natl Acad. Sci. USA 108(49), 19755-19760 (2011).
96. Pignatelli S, Lazzarotto T, Gatto MR et al. Cytomegalovirus gN genotypes distribution among congenitally infected newborns and their relationship with symptoms at birth and sequelae. Clin. Infect. Dis. 51(1), 33-41 (2010).
97. Pignatelli S, Dal MP, Rossini G, Landini MP. Genetic polymorphisms among human cytomegalovirus (HCMV) wild-type strains. Rev. Med. Virol. 14(6), 383-410 (2004).
98. Dal Monte P, Pignatelli S, Rossini G, Landini MP. Genomic variants among human cytomegalovirus (HCMV) clinical isolates: the glycoproteinn (gN) paradigm. Hum. Immunol. 65(5), 387-94 (2004)
99. Coaquette A, Bourgeois A, Dirand C, Varin A, Chen W, Herbein G. Mixed cytomegalovirus glycoprotein B genotypes in immunocompromised patients. Clin. Infect. Dis. 39(2), 155-161 (2004).
100. Gorzer I, Kerschner H, Redlberger-Fritz M, Puchhammer-Stockl E. Human cytomegalovirus (HCMV) genotype populations in immunocompetent individuals during primary HCMV infection. J. Clin. Virol. 48(2), 100-103 (2010).
101. Dieamant DC, Bonon SH, Peres RM et al. Cytomegalovirus (CMV) genotype in allogeneic hematopoietic stem cell transplantation. BMC Infect. Dis. 13, 310 (2013).
102. Banan AA, Yaghobi R, Ramzi M, Mehrabani D. Impact of human cytomegalovirus infection UL55-nested polymerase chain reaction method in hematopoietic stem cell transplant donors and recipients. Transplant Proc. 41(7), 2898-2899 (2009).
103. Arav-Boger R, Pass R. Viral load in congenital cytomegalovirus infection. Herpes 14(1), 17-22 (2007).
104. Neirukh T, Qaisi A, Saleh N et al. Seroprevalence of cytomegalovirus among pregnant women and hospitalized children in Palestine. BMC Infect. Dis. 13, 528 (2013).
105. Arav-Boger R, Boger YS, Foster CB, Boger Z. The use of artifcial neural networks in prediction of congenital CMV outcome from sequence data. Bioinform. Biol. Insights 2, 281-289 (2008).
106. Cekinovic D, Lisnic VJ, Jonjic S. Rodent models of congenital cytomegalovirus infection. Methods Mol. Biol. 1119, 289-310 (2014).
107. Belzile JP, Stark TJ, Yeo GW, Spector DH. Human cytomegalovirus infection of human embryonic stem cell-derived primitive neural stem cells is restricted at several steps but leads to the persistence of viral DNA. J. Virol. 88(8), 4021-4039 (2014).
108. Fishman JA, Emery V, Freeman R et al. Cytomegalovirus in transplantation-challenging the status quo. Clin. Transplant. 21(2), 149-158 (2007).
109. Rubin RH. The pathogenesis and clinical management of cytomegalovirus infection in the organ transplant recipient: the end of the 'silo hypothesis'. Curr. Opin. Infect. Dis. 20(4), 399-407 (2007).
110. Ramanan P, Razonable RR. Cytomegalovirus infections in solid organ transplantation: a review. Infect. Chemother. 45(3), 260-271 (2013).
111. Powers C, Fruh K. Rhesus CMV. An emerging animal model for human CMV. Med. Microbiol. Immunol. 197(2), 109-115 (2008).
112. Hummel M, Zhang Z, Yan S et al. Allogeneic transplantation induces expression of cytomegalovirus im med iate-early genes in vivo: a model for reactivation from latency. J. Virol. 75(10), 4814-4822 (2001).
113. Zhang Z, Kim SJ, Varghese T, Thomas G, Hummel M, Abecassis M. TNF receptor independent activation of the cytomegalovirus major immediate early enhancer in response to transplantation. Transplantation 85(7), 1039-1045 (2008).
114. Ljungman P, Brandan R. Factors infuencing cytomegalovirus seropositivity in stem cell transplant patients and donors. Haematologica 92 (8), 1139-1142 (2007).
115. Ogawa-Goto K, Ueno T, Oshima K et al. Detection of active human cytomegalovirus by the promyelocytic leukemia body assay in cultures of PBMCs from patients undergoing hematopoietic stem cell transplantation. J. Med. Virol. 84(3), 479-486 (2012).
116. Ariza-Heredia EJ, Nesher L, Chemaly RF. Cytomegalovirus diseases after hematopoietic stem cell transplantation: a mini-review. Cancer Lett. 342(1), 1-8 (2014).
117. Gerna G, Lilleri D, Chiesa A et al. Virologic and immunologic monitoring of cytomegalovirus to guide preemptive therapy in solid-organ transplantation. Am. J. Transplant. 11(11), 2463-2471 (2011).
118. Gayoso I, Cantisan S, Cerrato C et al. Clinical factors infuencing phenotype of HCMV-specifc CD8+ T cells and HCMV-induced interferon-gamma production after allogeneic stem cells transplantation. Clin. Dev. Immunol. 347213 (2013).
119. Marty FM, Winston DJ, Rowley SD et al. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation. N. Engl. J. Med. 369(13), 1227-1236 (2013).
120. Springer KL, Weinberg A. Cytomegalovirus infection in the era of HAART: fewer reactivations and more immunity. J. Antimicrob. Chemother. 54(3), 582-586 (2004).
121. Ford N, Shubber Z, Saranchuk P et al. Burden of HIV-related cytomegalovirus retinitis in resource-limited settings: a systematic review. Clin. Infect. Dis. 57(9), 1351-1361 (2013).
122. Kumar A, Abbas W, Herbein G. TNF and TNF receptor superfamily members in HIV infection: new cellular targets for therapy? Mediators. Infamm. 484378 (2013).
123. Simon CO, Seckert CK, Dreis D, Reddehase MJ, Grzimek NK. Role for tumor necrosis factor alpha in murine cytomegalovirus transcriptional reactivation in latently infected lungs. J. Virol. 79(1), 326-340 (2005).
124. Le V T, Trilling M, Hengel H. The cytomegaloviral protein pUL138 acts as potentiator of tumor necrosis factor (TNF) receptor 1 surface density to enhance ULb′-encoded modulation of TNF-alpha signaling. J. Virol. 85(24), 13260-13270 (2011).
125. Montag C, Wagner JA, Gruska I, Vetter B, Wiebusch L, Hagemeier C. The latency-associated UL138 gene product of human cytomegalovirus sensitizes cells to tumor necrosis factor alpha (TNF-alpha) signaling by upregulating TNF-alpha receptor 1 cell surface expression. J. Virol. 85(21), 11409-11421 (2011).
126. Iyer J V, Connolly J, Agrawal R et al. Cytokine analysis of aqueous humor in HIV patients with cytomegalovirus retinitis. Cytokine 64(2), 541-547 (2013).
127. Smith MS, Goldman DC, Bailey AS et al. Granulocyte-colony stimulating factor reactivates human cytomegalovirus in a latently infected humanized mouse model. Cell Host Microbe 8(3), 284-291 (2010).
128. Hornef MW, Bein G, Fricke L et al. Coincidence of Epstein-Barr virus reactivation, cytomegalovirus infection, and rejection episodes in renal transplant recipients. Transplantation 60(5), 474-480 (1995).
129. Khameneh ZR, Soin J, Durlik M, Lao M, Paczek L, Gaciong Z. Factors affecting reactivation of Epstein-Barr virus infection after kidney allograft transplantation. Ann. Transplant. 4(2), 18-22 (1999).
130. Arcenas R, Widen RH. Epstein-Barr virus reactivation after superinfection of the BJAB-B1 and P3HR-1 cell lines with cytomegalovirus. BMC Microbiol. 2, 20 (2002).
131. Barton ES, White DW, Cathelyn JS et al. Herpesvirus latency confers symbiotic protection from bacterial infection. Nature 447(7142), 326-329 (2007).
132. Saghafan-Hedengren S, Sohlberg E, Theorell J et al. Epstein-Barr virus coinfection in children boosts cytomegalovirus-induced differentiation of natural killer cells. J. Virol. 87(24), 13446-13455 (2013).
133. DesJardin JA, Gibbons L, Cho E et al. Human herpesvirus 6 reactivation is associated with cytomegalovirus infection and syndromes in kidney transplant recipients at risk for primary cytomegalovirus infection. J. Infect. Dis. 178 (6), 1783-1786 (1998).
134. Lautenschlager I, Linnavuori K, Lappalainen M, Suni J, Hockerstedt K. HHV-6 reactivation is often associated with CMV infection in liver transplant patients. Transpl. Int. 13(Suppl 1), S351-S353 (2000).
135. Herbein G, Strasswimmer J, Altieri M, Woehl-Jaegle ML, Wolf P, Obert G. Longitudinal study of human herpesvirus 6 infection in organ transplant recipients. Clin. Infect. Dis. 22(1), 171-173 (1996).
136. Sampaio AM, Guardia AC, Milan A et al. Co-infection and clinical impact of human herpesvirus 5 and 6 in liver transplantation. Transplant. Proc. 44(8), 2455-2458 (2012).
137. Guardia AC, Stucchi RS, Milan A, Costa SC, Boin IF. Human herpesvirus-6 and cytomegalovirus DNA in liver donor biopsies and their correlation with HLA matches and acute cellular rejection. Braz. J. Infect. Dis. 18(2), 220-224 (2014).
138. Duan YL, Ye HQ, Zavala AG et al. Maintenance of large numbers of virus genomes in human cytomegalovirus-infected T98G glioblastoma cells. J. Virol. 88(7), 3861-3873 (2014).
139. Khan Z, Yaiw KC, Wilhelmi V et al. Human cytomegalovirus immediate early proteins promote degradation of connexin 43 and disrupt gap junction communication. Implications for a role in gliomagenesis. Carcinogenesis 35(1), 145-154 (2014).
140. Lepiller Q, Tripathy MK, Di Martino V, Kantelip B, Herbein G. Increased HCMV seroprevalence in patients with hepatocellular carcinoma. Virol. J. 8, 485 (2011).
141. Lepiller Q, Khan KA, Di Martino V, Herbein G. Cytomegalovirus and tumors: two players for one goalimmune escape. Open. Virol. J. 5, 60-69 (2011).
142. Lepiller Q, Abbas W, Kumar A, Tripathy MK, Herbein G. HCMV activates the IL-6-JAK-STAT3 axis in HepG2 cells and primary human hepatocytes. PLoS One 8(3), e59591 (2013).
143. Michaelis M, Doerr HW, Cinatl J. The story of human cytomegalovirus and cancer: increasing evidence and open questions. Neoplasia 11(1), 1-9 (2009).
144. Bongers G, Maussang D, Muniz LR et al. The cytomegalovirus-encoded chemokine receptor US28 promotes intestinal neoplasia in transgenic mice. J. Clin. Invest 120(11), 3969-3978 (2010).
145. Cobbs CS, Harkins L, Samanta M et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 62(12), 3347-3350 (2002).
146. Dziurzynski K, Chang SM, Heimberger AB et al. Consensus on the role of human cytomegalovirus in glioblastoma. Neuro. Oncol. 14(3), 246-255 (2012).
147. Rahbar A, Orrego A, Peredo I et al. Human cytomegalovirus infection levels in glioblastoma multiforme are of prognostic value for survival. J. Clin. Virol. 57(1), 36-42 (2013).
148. Yamashita Y, Ito Y, Isomura H, Takemura N et al. Lack of presence of the human cytomegalovirus in human glioblastoma. Mod. Pathol. 27(7), 922-929 (2014).
149. Della CM, Falco M, Muccio L, Bertaina A, Locatelli F, Moretta A. Impact of HCMV infection on NK cell development and function after HSCT. Front Immunol. 4, 458 (2013).
150. Courivaud C, Bamoulid J, Gaugler B et al. Cytomegalovirus exposure, immune exhaustion and cancer occurrence in renal transplant recipients. Transpl. Int. 25(9), 948-955 (2012).
151. La RC, Diamond DJ. The immune response to human C M V. Future Virol. 7(3), 279-293 (2012).
152. Lopez-Verges S, Milush JM, Schwartz BS et al. Expansion of a unique CD57(+)NKG2Chi natural killer cell subset during acute human cytomegalovirus infection. Proc. Natl Acad. Sci. USA 108(36), 14725-14732 (2011).
153. Della CM, Falco M, Podesta M et al. Phenotypic and functional heterogeneity of human NK cells developing after umbilical cord blood transplantation: a role for human cytomegalovirus? Blood 119(2), 399-410 (2012).
154. Della CM, Falco M, Bertaina A et al. Human cytomegalovirus infection promotes rapid maturation of NK cells expressing activating killer Ig-like receptor in patients transplanted with NKG2C-/-umbilical cord blood. J. Immunol. 192 (4), 1471-1479 (2014).
155. Foley B, Cooley S, Verneris MR et al. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C+ natural killer cells with potent function. Blood 119(11), 2665-2674 (2012).
156. Velardi A. Natural revenge over cytomegalovirus. Blood 119(11), 2438-2439 (2012).